Status: Recruiting
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with moderate-to-severe inflammatory bowel disease.
Participants needed: 88
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Guangdong Hengrui Pharmaceutical Co., LtdUpdated: Sep 25, 2026Locations: 1
Eligibility criteria
Voluntarily signed the informed consent form [+4]
Suspected allergy to the study drug or any component of the study drug [+9]